LNP-nCoVsaRNA is being developed by the Imperial College of London.Current Status: The vaccine is under a phase I trial.Mode of Action: LNP-nCoVsaRNA contains bits of genetic code (called self-amplifying RNA), rather than bits of the virus, that holds all the information needed to make the spike protein. Once injected into the muscle, the cells should produce copies of the spike protein found on the outside of the virus. In response to spike proteins, the immune system will start producing antibodies and in the process also creates a lasting memory of the spike proteins. In the future, when coronavirus attacks the body, the immune system will recognize the spike proteins of the virus and will fight it off.Next Milestone:Interim results from the phase I trial are expected to be available by the end of August 2020.